PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1593755
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1593755
Opioid Analgesics Market Assessment, By Product Type, By Application, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
Global opioid analgesics market is projected to witness a CAGR of 4.03% during the forecast period 2024-2031, growing from USD 45.21 billion in 2023 to USD 62.02 billion in 2031. The market demand for opioid analgesic pharmaceutical products is anticipated to thrive in the forecast period for multimodal pain when non-opioid drugs or physical therapy is ineffective for treating chronic pain issues. The quick onset of action and high efficacy of various treatment options available in the market are increasing the demand for opioid analgesics.
Also, an increase in the prevalence of chronic pain conditions such as cancer, arthritis, and lower back pain, heart disease has led to an increase in demand for opioid analgesics in the market. Advancements in new formulations by resolving safety concerns around the use of opioids and abuse-deterrent formulation technology are boosting the growth of the market. Over the past few years, drug misuse has emerged as a major global health concern. The prescription of opioids for pain relief has increased substantially, and so has the rate of abuse for them. Controlling drug addiction and prescription opioid overdoses can be effectively managed using abuse-deterrent formations. The FDA is pushing for the development of abuse-deterrent formulations (ADFs) for prescription opioids in an effort to address the opioid abuse problem. The government acknowledges that while abuse-deterrent opioids are a step toward potentially less abusive medicines, they are neither abuse nor addiction-proof. For instance, In February 2024, Hikma Pharmaceuticals PLC announced the launch of Fentanyl Citrate Injection, USP 25mcg/0.5mL and 50mcg/mL. As noted by requirements, it is used for anesthesia periods, premedication, induction, and maintenance in the immediate postoperative period. The injection is also used as an adjunct to narcotic analgesia in general or regional anesthesia.
Increasing Prevalence of Cancer to Boost the Market
Chronic pain is present in 20% to 50% of cancer patients. About 80% of advanced-stage cancer patients have moderate to severe pain. One meta-analysis of pooled data from 52 studies found that more than half of the participants reported pain. Cancer pain and pain flares are more likely to occur in younger patients than older patients. Advances in understanding the biological mechanisms of cancer-related pain have led to better-targeted and more effective use of opioids. The global burden of cancer has grown recently, so research into finding new therapies and improving patient outcomes has increased. The increase in the incidence of cancer directly relates to a greater need for pain management strategies that are efficacious. The major driver for the opioid analgesic market is increased research and development initiatives being taken for the treatment of cancer. It is a reality that an increase in knowledge of cancer-related pain is substantially increasing the use of opioid analgesics for pain management. This trend underlines the role of pain relief in cancer care, highlighting a need for providers to balance opioid use with strategies for minimizing misuse and dependence, thus leading to safer and more effective patient care. Researchers are increasingly focusing on developing new therapies and evaluating their efficacy and safety.
Increasing Prevalence of Chronic Pain
The growth of the opioid market is driven by the increasing prevalence of chronic pain, which is affecting millions of individuals globally with the condition such as chronic conditions, including arthritis, fibromyalgia, and neuropathic pain, are increasingly becoming common, and patients are seeking effective pain management solutions to enhance their quality of life. With the increasing prevalence of chronic pain, coupled with an aging population more likely to suffer from this condition, healthcare providers turn to opioids as the first line of treatment. Continued research and development for opioid formulations is also being undertaken to optimize their efficacy with minimal side effects, therefore fueling additional growth in the market. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, patients and providers towards the management of chronic pain with opioids as part of treatment.
In August 2022, Adalvo Limited announced that the company had acquired its first branded product, Onsolis, after finalizing a deal with a leading US-based specialty pharmaceutical company. The brand is an opioid analgesic used in the management of persistent breakthrough pain in cancer patients who are already receiving and tolerant to opioid therapy for their underlying cancer pain. The ongoing development of opioid formulations continues toward improved efficacy but with reduced potential side effects and related dependency risks. These advances address the dual considerations of efficacy and safety in pain relief, nudging patients and providers toward the management of chronic pain with opioids as part of treatment.
Codeine Segment to Dominate the Opioid Analgesics Market
The codeine market is likely to lead in the opioid analgesics market in view of its widespread use and application in clinical conditions for pain management. Codeine is a naturally occurring opioid and is most often preferred as an alternative due to its effective analgesic properties along with relatively lower severity of side effects compared with stronger opioids, making it a popular medicine for the treatment of mild to moderate pain, especially in outpatient settings. In addition, the availability of codeine in several formulations involving combination products with acetaminophen or aspirin makes it more attractive to prescribers and patients. The increasing prevalence of chronic pain disorders and the demand for better pain relief interventions will keep supporting this segment. Continued studies and development of codeine as the best therapeutic agent ensure that the opioid analgesics market will be dominated by codeine. There are several studies that are currently undergoing on Codeine, for instance, the National Superiority Clinical Trial to assess the combination of fixed dosage of Dipyrone and Codeine comparing the isolated use of components in the control of moderate to severe pain after open pelvic-abdominal surgery.
North America Dominates the Opioid Analgesics Market
North America dominates the opioid analgesics markets due to the high prevalence of chronic pain, neuropathic pain, and postoperative surgical pain. Chronic pain is a condition that affects the daily life of many adults in the United States. According to the Centers for Disease Control and Prevention (CDC), almost 21% of the U.S. population, i.e., 51.6 million adults' population, is affected by chronic pain, and 6.9% (17.1 million people) experienced severe chronic pain (i.e., chronic pain that causes significant limitation of daily activities), with a higher prevalence among non-Hispanic American Indians or Alaskans. According to CDC reports that analyzed data from the National Health Interview Survey, chronic pain lasts for at least three months and usually affects the ability to function and work. In contrast, high-impact chronic pain occurs when chronic pain significantly reduces the activities of daily living. Chronic pain is a major public health problem in the United States. The healthcare cost of chronic pain in America is estimated at USD 635 billion per year, according to a JAMA Network Open article.
Future Market Scenario (2024-2031F)
In the opioid analgesic market over the past 10 years, considerable fluctuations have been observed mainly due to the increase in opioid crisis and regulatory control. Nevertheless, future scenarios will be formed through the development of healthcare practice, regulating the framework and achievements in pain management. Pharmaceutical companies are investing in developing abuse-deterrent formulations. These innovations can restore trust between doctors and patients and increase market acceptance. The opioid analgesics market is expected to remain stable, with growth potential in certain areas due to innovation and a growing understanding of pain management. Companies that focus on developing safer opioid formulations and alternative pain management solutions are likely to see growth, which is anticipated to drive the opioid analgesics market. Collaboration with regulators and healthcare providers is key to shaping a responsible future for the opioid analgesics market.
Key Players Landscape and Outlook
The multimodal pain management opioid analgesics market is highly dynamic, with several players like Pfizer Inc., Johnson & Johnson Services, Inc., Teva Pharmaceuticals Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceuticals Industries Ltd., Bayer AG, Abbott Laboratories, Purdue Pharma L.P., Hikma Pharmaceuticals PLC., Sanofi S.A. Corporation Opioid Analgesics. Significant market activities have been reported in recent times, including distribution agreements and acquisitions alongside several product launches. In May 2023 Trevena Inc. a biopharmaceutical company, announced that its partner, Jiangsu Nhwa Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has received approval from China's National Medical Products Administration (NMPA) for Olinvyk (oliceridine). Olinvyk is an opioid agonist indicated to manage pain severe enough to require an intravenous opioid analgesic in adult patients whose alternative treatments are inadequate.
In April 2023, Rusan Pharma Ltd. submitted a proposal to the commission for approval to manufacture and market methadone oral solution 1 mg/ml, as well as an application for a BA/BE research and clinical trial exemption. Methadone oral solution 1 mg/ml is already approved product. But this firm is required to submit BA/BE study protocol for further review by the committee.
Table of Contents
1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Opioid Analgesics Market Outlook, 2017-2031F
- 4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
- 4.2. Market Share Analysis & Forecast
- 4.2.1. By Products Type
- 4.2.1.1. Codeine
- 4.2.1.2. Morphine
- 4.2.1.3. Oxycodone
- 4.2.1.4. Hydrocodone
- 4.2.1.5. Methadone
- 4.2.1.6. Meperidine
- 4.2.1.7. Fentanyl
- 4.2.1.8. Hydromorphone
- 4.2.1.9. Oxymorphone
- 4.2.1.10. Dextromethorphan
- 4.2.1.11. Tramadol
- 4.2.1.12. Others
- 4.2.2. By Application
- 4.2.2.1. Chronic Pain
- 4.2.2.2. Acute Pain
- 4.2.3. By Route of Administration
- 4.2.3.1. Oral
- 4.2.3.2. Injectable
- 4.2.3.3. Others
- 4.2.4. By Distribution
- 4.2.4.1. Hospital Pharmacy
- 4.2.4.2. Retail Pharmacy
- 4.2.4.3. Others
- 4.2.5. By Region
- 4.2.5.1. North America
- 4.2.5.2. Europe
- 4.2.5.3. Asia-Pacific
- 4.2.5.4. South America
- 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
- 4.2.1. By Products Type
- 4.3. Market Map Analysis, 2023
- 4.3.1. By Product Type
- 4.3.2. By Application
- 4.3.3. By Route of Administration
- 4.3.4. By Distribution
- 4.3.5. By Region
5. North Opioid Analgesics Market Outlook, 2017-2031F*
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Products Type
- 5.2.1.1. Codeine
- 5.2.1.2. Morphine
- 5.2.1.3. Oxycodone
- 5.2.1.4. Hydrocodone
- 5.2.1.5. Methadone
- 5.2.1.6. Meperidine
- 5.2.1.7. Fentanyl
- 5.2.1.8. Hydromorphone
- 5.2.1.9. Oxymorphone
- 5.2.1.10. Dextromethorphan
- 5.2.1.11. Tramadol
- 5.2.1.12. Others
- 5.2.2. By Application
- 5.2.2.1. Chronic Pain
- 5.2.2.2. Acute Pain
- 5.2.3. By Route of Administration
- 5.2.3.1. Oral
- 5.2.3.2. Injectable
- 5.2.3.3. Others
- 5.2.4. By Distribution
- 5.2.4.1. Hospital Pharmacy
- 5.2.4.2. Retail Pharmacy
- 5.2.4.3. Others
- 5.2.5. By Country Share
- 5.2.5.1. United States
- 5.2.5.2. Canada
- 5.2.5.3. Mexico
- 5.2.1. By Products Type
- 5.3. Country Market Assessment
- 5.3.1. United States Opioids Analgesics Market Outlook, 2017-2031F*
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.1.1.1. By Value
- 5.3.1.2. Market Share Analysis & Forecast
- 5.3.1.2.1. By Product type
- 5.3.1.2.1.1. Codeine
- 5.3.1.2.1.2. Morphine
- 5.3.1.2.1.3. Oxycodone
- 5.3.1.2.1.4. Hydrocodone
- 5.3.1.2.1.5. Methadone
- 5.3.1.2.1.6. Meperidine
- 5.3.1.2.1.7. Fentanyl
- 5.3.1.2.1.8. Hydromorphone
- 5.3.1.2.1.9. Oxymorphone
- 5.3.1.2.1.10. Dextromethorphan
- 5.3.1.2.1.11. Tramadol
- 5.3.1.2.1.12. Others
- 5.3.1.2.2. By Application
- 5.3.1.2.2.1. Chronic Pain
- 5.3.1.2.2.2. Acute Pain
- 5.3.1.2.3. By Route of Administration
- 5.3.1.2.3.1. Oral
- 5.3.1.2.3.2. Injectable
- 5.3.1.2.3.3. Others
- 5.3.1.2.4. By Distribution
- 5.3.1.2.4.1. Hospitals Pharmacy
- 5.3.1.2.4.2. Retail Pharmacy
- 5.3.1.2.4.3. Others
- 5.3.1.2.1. By Product type
- 5.3.1.1. Market Size Analysis & Forecast
- 5.3.2. Canada
- 5.3.3. Mexico
- 5.3.1. United States Opioids Analgesics Market Outlook, 2017-2031F*
All segments will be provided for all regions and countries covered
6. Europe Opioid Analgesics Market Outlook, 2017-2031F
- 6.1. Germany
- 6.2. France
- 6.3. Italy
- 6.4. United Kingdom
- 6.5. Russia
- 6.6. Netherlands
- 6.7. Spain
- 6.8. Poland
7. Asia-Pacific Opioids Analgesics Market Outlook, 2017-2031F
- 7.1. India
- 7.2. China
- 7.3. Japan
- 7.4. Australia
- 7.5. Vietnam
- 7.6. South Korea
- 7.7. Indonesia
- 7.8. Philippines
8. South America Opioid Analgesics Market Outlook, 2017-2031F
- 8.1. Brazil
- 8.2. Argentina
9. Middle East and Africa Opioid Analgesics Market Outlook, 2017-2031F
- 9.1. Saudi Arabia
- 9.2. UAE
- 9.3. South Africa
- 9.4. Israel
10. Demand Supply Analysis
11. Import and Export Analysis
12. Value Chain Analysis
13. Porter's Five Forces Analysis
14. PESTLE Analysis
15. Pricing Analysis
16. Market Dynamics
- 16.1. Market Drivers
- 16.2. Market Challenges
17. Market Trends and Developments
18. Regulatory Framework and Innovation
- 18.1. Clinical Trials
- 18.2. Regulatory Approvals
19. Patent Landscape
20. Case Studies
21. Competitive Landscape
- 21.1. Competition Matrix of Top 5 Market Leaders
- 21.2. SWOT Analysis for Top 5 Players
- 21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Pfizer Inc.
- 21.3.1.1. Company Details
- 21.3.1.2. Key Management Personnel
- 21.3.1.3. Products and Services
- 21.3.1.4. Financials (As Reported)
- 21.3.1.5. Key Market Focus and Geographical Presence
- 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 21.3.2. Johnson & Johnson Services, Inc.
- 21.3.3. Teva Pharmaceuticals Industries Ltd.
- 21.3.4. Endo Pharmaceuticals Inc.
- 21.3.5. Sun Pharmaceuticals Industries Ltd.
- 21.3.6. Bayer AG
- 21.3.7. Abbott Laboratories
- 21.3.8. Purdue Pharma L.P.
- 21.3.9. Hikma Pharmaceuticals PLC.
- 21.3.10. Sanofi S.A.
- 21.3.1. Pfizer Inc.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
22. Strategic Recommendations
23. About Us and Disclaimer
List of Tables
- Table 1. Pricing Analysis of Products from Key Players
- Table 2. Competition Matrix of Top 5 Market Leaders
- Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 2. Global Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 3. Global Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 4. Global Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 5. Global Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 6. Global Opioid Analgesics Market Share (%), By Region, 2017-2031F
- Figure 7. North America Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 8. North America Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 9. North America Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 10. North America Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 11. North America Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 12. North America Opioid Analgesics Market Share (%), By Country, 2017-2031F
- Figure 13. United States Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 14. United States Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 15. United States Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 16. United States Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 17. United States Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 18. Canada Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 19. Canada Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 20. Canada Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 21. Canada Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 22. Canada Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 23. Mexico Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 24. Mexico Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 25. Mexico Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 26. Mexico Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 27. Mexico Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 28. Europe Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 29. Europe Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 30. Europe Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 31. Europe Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 32. Europe Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 33. Europe Opioid Analgesics Market Share (%), By Country, 2017-2031F
- Figure 34. Germany Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 35. Germany Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 36. Germany Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 37. Germany Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 38. Germany Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 39. France Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 40. France Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 41. France Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 42. France Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 43. France Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 44. Italy Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 45. Italy Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 46. Italy Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 47. Italy Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 48. Italy Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 49. United Kingdom Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 50. United Kingdom Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 51. United Kingdom Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 52. United Kingdom Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 53. United Kingdom Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 54. Russia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 55. Russia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 56. Russia Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 57. Russia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 58. Russia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 59. Netherlands Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 60. Netherlands Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 61. Netherlands Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 62. Netherlands Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 63. Netherlands Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 64. Spain Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 65. Spain Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 66. Spain Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 67. Spain Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 68. Spain Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 69. Turkey Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 70. Turkey Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 71. Turkey Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 72. Turkey Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 73. Turkey Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 74. Poland Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 75. Poland Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 76. Poland Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 77. Poland Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 78. Poland Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 79. South America Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 80. South America Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 81. South America Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 82. South America Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 83. South America Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 84. South America Opioid Analgesics Market Share (%), By Country, 2017-2031F
- Figure 85. Brazil Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 86. Brazil Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 87. Brazil Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 88. Brazil Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 89. Brazil Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 90. Argentina Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 91. Argentina Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 92. Argentina Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 93. Argentina Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 94. Argentina Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 95. Asia-Pacific Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 96. Asia-Pacific Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 97. Asia-Pacific Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 98. Asia-Pacific Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 99. Asia-Pacific Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 100. Asia-Pacific Opioid Analgesics Market Share (%), By Country, 2017-2031F
- Figure 101. India Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 102. India Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 103. India Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 104. India Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 105. India Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 106. China Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 107. China Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 108. China Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 109. China Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 110. China Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 111. Japan Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 112. Japan Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 113. Japan Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 114. Japan Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 115. Japan Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 116. Australia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 117. Australia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 118. Australia Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 119. Australia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 120. Australia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 121. Vietnam Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 122. Vietnam Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 123. Vietnam Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 124. Vietnam Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 125. Vietnam Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 126. South Korea Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 127. South Korea Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 128. South Korea Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 129. South Korea Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 130. South Korea Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 131. Indonesia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 132. Indonesia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 133. Indonesia Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 134. Indonesia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 135. Indonesia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 136. Philippines Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 137. Philippines Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 138. Philippines Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 139. Philippines Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 140. Philippines Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 141. Middle East & Africa Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 142. Middle East & Africa Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 143. Middle East & Africa Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 144. Middle East & Africa Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 145. Middle East & Africa Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 146. Middle East & Africa Opioid Analgesics Market Share (%), By Country, 2017-2031F
- Figure 147. Saudi Arabia Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 148. Saudi Arabia Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 149. Saudi Arabia Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 150. Saudi Arabia Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 151. Saudi Arabia Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 152. UAE Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 153. UAE Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 154. UAE Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 155. UAE Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 156. UAE Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 157. South Africa Opioid Analgesics Market, By Value, In USD Billion, 2017-2031F
- Figure 158. South Africa Opioid Analgesics Market Share (%), By Product Type, 2017-2031F
- Figure 159. South Africa Opioid Analgesics Market Share (%), By Application, 2017-2031F
- Figure 160. South Africa Opioid Analgesics Market Share (%), By Route of Administration, 2017-2031F
- Figure 161. South Africa Opioid Analgesics Market Share (%), By Distribution, 2017-2031F
- Figure 162. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 165. By Distribution Map-Market Size (USD Billion) & Growth Rate (%), 2023
- Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
